Nicholas Waters, CEO, presents at ProHearings capital market day

October 19, 2020 Read More >

Nicholas Waters, CEO, presents Redeye Neurology seminar

October 16, 2020 Read More >

IRLAB’s mesdopetam IND accepted by the US FDA

October 1, 2020 Regulatory

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the U.S. Food and Drug Administration (FDA) has accepted IRLAB’s investigational new drug application (IND) for the drug candidate mesdopetam (IRL790). The acceptance of the IND will allow IRLAB to include US patients in the upcoming clinical trial in Parkinson’s disease in accordance with the study protocol submitted with the IND application. The planned Phase IIb/III study for mesdopetam will thus include hospitals and enrol patients in the US and Europe. Mesdopetam is in development for the treatment of levodopa-induced dyskinesias in Parkinson’s disease, PD-LIDs, with the objective to increase daily good ON-time.

Read More >

IR contact

Viktor Siewertz, CFO
+46(0)72 710 70 70